Профилактика инсульта, когнитивных нарушений и деменции у пациентов с артериальной гипертензией на этапе оказания первичной медико-санитарной помощи

1. Warlow C, Sudlow C, Dennis M et al. Stroke. Lancet 2003; 362 (9391): 1211–24.
2. Swerdel JN, Rhoads GG, Cheng JQ et al. Myocardial Infarction Data Acquisition System (MIDAS 29) Study Group. Ischemic Stroke Rate Increases in Young Adults: Evidence for a Generational Effect? J Am Heart Assoc 2016; 5 (12).
3. Heart Disease and Stroke Statistics–2017 Update: A Report From the American Heart Association. http://circ.ahajournals.org/content/early/2017/01/25/CIR.0000000000000485
4. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте: Методическое пособие для врачей. М., 2005. / Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste: Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
5. Яхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврологический журн. 2006; 11 (Прил. 1): 4–12. / Iakhno N.N. Kognitivnye rasstroistva v nevrologicheskoi klinike. Nevrologicheskii zhurn. 2006; 11 (Pril. 1): 4–12. [in Russian]
6. Захаров В.В. Принципы ведения пациентов с когнитивными нарушениями без деменции. Рус. мед. журн. 2008; 12: 1645–9. / Zakharov V.V. Printsipy vedeniia patsientov s kognitivnymi narusheniiami bez dementsii. Rus. med. zhurn. 2008; 12: 1645–9. [in Russian]
7. DiCarlo A, Baldereschi M, Amaducci L et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Ger Soc 2000; 48: 775–82.
8. Захаров В.В., Яхно Н.Н. Нарушения памяти. М.: ГЭОТАР-Мед., 2003. / Zakharov V.V., Iakhno N.N. Narusheniia pamiati. M.: GEOTAR-Med., 2003. [in Russian]
9. Apostolo J, Holland C, O'Connell MD et al. Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas 2016; 83: 83–93.
10. Graham JE, Rockwood K, Beattie EL et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349: 1793–6.
11. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при цереброваскулярных заболеваниях. Эффективная фармакотерапия. 2014; 1: 14–21. / Zakharov V.V., Vakhnina N.V. Kognitivnye narusheniia pri tserebrovaskuliarnykh zabolevaniiakh. Effektivnaia farmakoterapiia. 2014; 1: 14–21. [in Russian]
12. Srikanth VK, Thrift AG, Saling MM et al. Increased risk of cognitive impairment 3 months after mild to moderate first-ever stroke: a Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke 2003; 34 (5): 1136-43. Epub 2003 Apr 17.
13. Rasquin SM, Verhey FR, van Oostenbrugge RJ et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry 2004; 75 (11): 1562–7.
14. Sachdev PS, Brodaty H, Valenzuela MJ et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord 2006; 21 (5–6): 275–83. Epub 2006 Feb 10.
15. Ihle-Hansen H, Thommessen B, Wyller TB et al. Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord 2011;32(6):401-7. DOI: 10.1159/000335361. Epub 2012 Feb 3.
16. Захаров В.В., Вахнина Н.В. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2011; 3 (2): 8–16. / Zakharov V.V., Vakhnina N.V. Insul't i kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2011; 3 (2): 8–16. [in Russian]
17. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012. / Parfenov VA, Khasanova DR. Ishemicheskii insul't. M.: MIA, 2012. [in Russian]
18. Lisabeth LD, Sanchez BN, Baek J et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke 2014; 45 (4): 1096–101.
19. Ivan CS, Seshadri S, Beiser A et al. Dementia after stroke: the Framingham Study. Stroke 2004; 35 (6): 1264–8. Epub 2004 Apr 29.
20. Srikanth VK, Anderson JF, Donnan GA et al. Progressive dementia after first-ever stroke: a community-based follow-up study. Neurology 2004; 63 (5): 785–2.
21. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8 (11): 1006–18.
22. Захаров В.В., Вахнина Н.В. Особенности ведения пациентов с постинсультными когнитивными нарушениями. Атмосфера. Нервные болезни. 2011; 3: 14–20. / Zakharov V.V., Vakhnina N.V. Osobennosti vedeniia patsientov s postinsul'tnymi kognitivnymi narusheniiami. Atmosfera. Nervnye bolezni. 2011; 3: 14–20. [in Russian]
23. Вахнина Н.В. Профилактика и лечение постинсультных когнитивных нарушений. Эффективная фармакотерапия. 2014; 42 (4): 32–9. / Vakhnina N.V. Profilaktika i lechenie postinsul'tnykh kognitivnykh narushenii. Effektivnaia farmakoterapiia. 2014; 42 (4): 32–9. [in Russian]
24. Захаров В.В., Вахнина Н.В., Громова Д.О., Тараповская А.А. Диагностика и лечение когнитивных нарушений после инсульта. Мед. совет. 2015; 10: 14–21. / Zakharov V.V., Vakhnina N.V., Gromova D.O., Tarapovskaia A.A. Diagnostika i lechenie kognitivnykh narushenii posle insul'ta. Med. sovet. 2015; 10: 14–21. [in Russian]
25. Преображенская И.С., Науменко А.А. Патогенез, диагностика и терапия болезни Альцгеймера. Мед. совет. 2015; 5: 46–54. / Preobrazhenskaia I.S., Naumenko A.A. Patogenez, diagnostika i terapiia bolezni Al'tsgeimera. Med. sovet. 2015; 5: 46–54. [in Russian]
26. Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике. Мед. совет. 2015; 18: 41–4. / Kotov A.S., Eliseev Iu.V., Semenova E.I. Bolezn' Al'tsgeimera: ot teorii k praktike. Med. sovet. 2015; 18: 41–4. [in Russian]
27. Рекомендации Европейского Общества по АГ. 2013 год. URL: http://gipertonik.ru/recommendation-european-society. / Rekomendatsii Evropeiskogo Obshchestva po AG. 2013 god. URL: http://gipertonik.ru/recommendation-european-society. [in Russian]
28. Poole-Wilson PA, Lubsen J, Kirwan BA et al. On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.
29. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64.
30. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046–52.
31. Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
32. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
33. PATS Collaborating Group. Post-stroke antihypertensive treatment study: preliminary results. Clin Med J 1995; 108: 710–7.
34. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
35. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
36. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
37. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20.
38. Bufalino VJ, Masoudi FA, Stranne SK et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167–79.
39. Трухан Д.И., Мазуров А.Л. Легкие и умеренные когнитивные нарушения: актуальные вопросы диагностики и лечения на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2016; 18 (2): 74–80. / Trukhan D.I., Mazurov A.L. Mild to moderate cognitive impairment: current issues of diagnosis and treatment in primary health care. Consilium Medicum. 2016; 18 (2): 74–80. [in Russian]
40. Захаров В.В. Диагностика и лечение когнитивных нарушений.  Consilium Medicum. Неврология и Ревматология. (Прил.). 2014; 1: 21–7. / Zakharov V.V., Vakhnina N.V. Diagnosis and treatment of cognitive impairments. Neurology and Rheumatology. Consilium Medicum (Suppl.). 2014; 1: 21–7. [in Russian]
41. Dlugaj M, Winkler A, Weimar C et al. Anemia and Mild Cognitive Impairment in the German General Population. J Alzheimers Dis 2015; 49 (4): 1031–42.
42. Papachristou E, Ramsay SE, Papacosta O et al. The Test Your Memory cognitive screening tool: sociodemographic and cardiometabolic risk correlates in a population-based study of older British men. Int J Geriatr Psychiatry 2015 Oct 21.
43. Knopman DS, Beiser A, Machulda MM et al. Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology. 2015; 85 (19): 1712–21.
44. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. Climacteric 2015; 18 (5): 678–89.
45. Booker A, Jacob LE, Rapp M et al. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 2016 Jan 8; 1–7.
46. van Rooij FG, Kessels RP, Richard E et al. Cognitive Impairment in Transient Ischemic Attack Patients: A Systematic Review. Cerebrovasc Dis 2016; 42 (1–2): 1–9.
47. Tzivian L, Dlugaj M, Winkler A et al. Long-Term Air Pollution and Traffic Noise Exposures and Mild Cognitive Impairment in Older Adults: A Cross-Sectional Analysis of the Heinz Nixdorf Recall Study. Environ Health Perspect 2016 Feb 5.
48. Захаров В.В., Дроздова Е.А. Когнитивные нарушения у больных с черепно-мозговой травмой. Неврология, нейропсихиатрия, психосоматика. 2013; 4: 88–93. / Zakharov V.V., Drozdova E.A. Kognitivnye narusheniia u bol'nykh s cherepno-mozgovoi travmoi. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2013; 4: 88–93. [in Russian]
49. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при депрессии. Эффективная фармакотерапия. 2015; 1: 18–26. / Zakharov V.V., Vakhnina N.V. Kognitivnye narusheniia pri depressii. Effektivnaia farmakoterapiia. 2015; 1: 18–26. [in Russian]
50. Строков И.А., Захаров В.В., Строков К.И. Диабетическая энцефалопатия. Современное состояние проблемы. Доктор.Ру. 2013; 7–2: 29–35. / Strokov I.A., Zakharov V.V., Strokov K.I. Diabeticheskaia entsefalopatiia. Sovremennoe sostoianie problemy. Doktor.Ru. 2013; 7–2: 29–35. [in Russian]
51. Куимов А.Д., Голубкова М.Е. Коррекция когнитивных нарушений у больных с сердечно-сосудистыми заболеваниями. Неврология и Ревматология (Прил. к Consilium Medicum). 2012; 2: 49–51. / Kuimov A.D., Golubkova M.E. Korrektsiia kognitivnykh narushenii u bol'nykh s serdechno-sosudistymi zabolevaniiami. Neurology and Rheumatology (Suppl. to the Consilium Medicum). 2012; 2: 49–51. [in Russian]
52. Чухловина М.Л. Неврологические осложнения сердечно-сосудистых заболеваний. Справочник поликлинического врача. 2012; 8: 51–53. / Chukhlovina M.L. Nevrologicheskie oslozhneniia serdechno-sosudistykh zabolevanii. Handbook for Practitioners Doctors. 2012; 8: 51–3. [in Russian]
53. Захаров В.В., Вахнина Н.В., Остроумова О.Д. Коррекция когнитивных нарушений у пациента с артериальной гипертензией и сердечной недостаточностью: как сделать правильный выбор. Эффективная фармакотерапия. 2014; 12: 12–8. /Zakharov V.V., Vakhnina N.V., Ostroumova O.D. Korrektsiia kognitivnykh narushenii u patsienta s arterial'noi gipertenziei i serdechnoi nedostatochnost'iu: kak sdelat' pravil'nyi vybor. Effektivnaia farmakoterapiia. 2014; 12: 12–8. [in Russian]
54. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347–51.
55. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752–68.
56. Mason RP, Leeds PR, Jacob PF et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448–56.
57. Thibault O, Porter NM, Chen KC. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417–33.
58. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543–4.
59. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81–8.
60. Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease. Mt Sinai J Med 2010; 77: 43–9.
61. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589–97.
62. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631–6.
63. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103–13.
64. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8: 16–30.
65. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217–33.
66. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Ab accumulation by targeting both the production and the clearance of Ab across the blood-brain barrier. Mol Med 2011; 17 (3–4): 149–62.
67. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71–4.
68. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26: 157–63.
69. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20: 903–14.
70. Spinar J, Vitovec J. AII antagonists in the treatment of hypertension and prevention of CVA. Vnitr Lek 2013; 59 (1): 71–8.
71. Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents. Curr Med Res Opin 2013; 29 (9): 1045–54.
72. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014; 19 (6): 501–15.
73. Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160–9.
74. Остроумова О.Д. Профилактика инсульта и деменции у больных высокого риска. Consilium Medicum. 2015; 17 (10): 73–6. / Ostroumova O.D. Prevention of stroke and dementia in high-risk patients. Consilium Medicum. 2015;17 (10): 73–6. [in Russian]
75. Чурсина Т.Я., Михалев К.А. «Фармакологический лабиринт», или Поиски оптимальной комбинации. Артериальная гипертензия. 2012; 5: 32–8. / Chursina T.Ia., Mikhalev K.A. «Farmakologicheskii labirint», ili Poiski optimal'noi kombinatsii. Arterial'naia gipertenziia. 2012; 5: 32–8. [in Russian]
76. Корж А.Н., Говбах И.А. Рациональная комбинированная терапия артериальной гипертензии: оптимизация профилактики цереброваскулярных нарушений. Артериальная гипертензия. 2013; 5: 9–15. / Korzh A.N., Govbakh I.A. Ratsional'naia kombinirovannaia terapiia arterial'noi gipertenzii: optimizatsiia profilaktiki tserebrovaskuliarnykh narushenii. Arterial'naia gipertenziia. 2013; 5: 9–15. [in Russian]
77. Крючкова О.Н., Ицкова Е.А., Лутай Ю.А., Турна Э.Ю. Новые горизонты фиксированной антигипертензивной терапии. Крымский терапевтический журн. 2015; 17 (2): 41–8. / Kriuchkova O.N., Itskova E.A., Lutai Iu.A., Turna E.Iu. Novye gorizonty fiksirovannoi antigipertenzivnoi terapii. Krymskii terapevticheskii zhurn. 2015; 17 (2): 41–8. [in Russian]
78. Энанорм (Enanorm). Инструкция по применению, противопоказания, состав и цена. URL: http://www.rlsnet.ru/tn_index_id_49497.htm / Enanorm (Enanorm). Instruktsiia po primeneniiu, protivopokazaniia, sostav i tsena. URL: http://www.rlsnet.ru/tn_index_id_49497.htm [in Russian]
79. Трухан Д.И., Поздняков Ю.М. Актуальные аспекты рациональной фармакотерапии в кардиологии. Плюсы и минусы фиксированных и произвольных комбинаций антигипертензивных препаратов. Consilium Medicum. 2016; 18 (1): 25–31. / Trukhan D.I., Pozdnyakov Yu.M. Actual aspects of rational pharmacotherapy in cardiology. Pros and cons fixed and arbitrary combinations of antihypertensive drugs. Consilium Medicum. 2016; 18 (1): 25–31. [in Russian]
80. Трухан Д.И., Поздняков Ю.М. Лечение артериальной гипертензии проблемы реальной клинической практики. Справочник поликлинического врача. 2016; 3: 4–8. / Trukhan D.I., Pozdniakov Iu.M. Lechenie arterial'noi gipertenzii problemy real'noi klinicheskoi praktiki. Spravochnik poliklinicheskogo vracha. 2016; 3: 4–8. [in Russian]

________________________________________________

1. Warlow C, Sudlow C, Dennis M et al. Stroke. Lancet 2003; 362 (9391): 1211–24.
2. Swerdel JN, Rhoads GG, Cheng JQ et al. Myocardial Infarction Data Acquisition System (MIDAS 29) Study Group. Ischemic Stroke Rate Increases in Young Adults: Evidence for a Generational Effect? J Am Heart Assoc 2016; 5 (12).
3. Heart Disease and Stroke Statistics–2017 Update: A Report From the American Heart Association. http://circ.ahajournals.org/content/early/2017/01/25/CIR.0000000000000485
4. Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste: Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
5. Iakhno N.N. Kognitivnye rasstroistva v nevrologicheskoi klinike. Nevrologicheskii zhurn. 2006; 11 (Pril. 1): 4–12. [in Russian]
6. Zakharov V.V. Printsipy vedeniia patsientov s kognitivnymi narusheniiami bez dementsii. Rus. med. zhurn. 2008; 12: 1645–9. [in Russian]
7. DiCarlo A, Baldereschi M, Amaducci L et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Ger Soc 2000; 48: 775–82.
8. Zakharov V.V., Iakhno N.N. Narusheniia pamiati. M.: GEOTAR-Med., 2003. [in Russian]
9. Apostolo J, Holland C, O'Connell MD et al. Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas 2016; 83: 83–93.
10. Graham JE, Rockwood K, Beattie EL et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349: 1793–6.
11. Zakharov V.V., Vakhnina N.V. Kognitivnye narusheniia pri tserebrovaskuliarnykh zabolevaniiakh. Effektivnaia farmakoterapiia. 2014; 1: 14–21. [in Russian]
12. Srikanth VK, Thrift AG, Saling MM et al. Increased risk of cognitive impairment 3 months after mild to moderate first-ever stroke: a Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke 2003; 34 (5): 1136-43. Epub 2003 Apr 17.
13. Rasquin SM, Verhey FR, van Oostenbrugge RJ et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry 2004; 75 (11): 1562–7.
14. Sachdev PS, Brodaty H, Valenzuela MJ et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord 2006; 21 (5–6): 275–83. Epub 2006 Feb 10.
15. Ihle-Hansen H, Thommessen B, Wyller TB et al. Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord 2011;32(6):401-7. DOI: 10.1159/000335361. Epub 2012 Feb 3.
16. Zakharov V.V., Vakhnina N.V. Insul't i kognitivnye narusheniia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2011; 3 (2): 8–16. [in Russian]
17. Parfenov VA, Khasanova DR. Ishemicheskii insul't. M.: MIA, 2012. [in Russian]
18. Lisabeth LD, Sanchez BN, Baek J et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke 2014; 45 (4): 1096–101.
19. Ivan CS, Seshadri S, Beiser A et al. Dementia after stroke: the Framingham Study. Stroke 2004; 35 (6): 1264–8. Epub 2004 Apr 29.
20. Srikanth VK, Anderson JF, Donnan GA et al. Progressive dementia after first-ever stroke: a community-based follow-up study. Neurology 2004; 63 (5): 785–2.
21. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8 (11): 1006–18.
22. Zakharov V.V., Vakhnina N.V. Osobennosti vedeniia patsientov s postinsul'tnymi kognitivnymi narusheniiami. Atmosfera. Nervnye bolezni. 2011; 3: 14–20. [in Russian]
23. Vakhnina N.V. Profilaktika i lechenie postinsul'tnykh kognitivnykh narushenii. Effektivnaia farmakoterapiia. 2014; 42 (4): 32–9. [in Russian]
24. Zakharov V.V., Vakhnina N.V., Gromova D.O., Tarapovskaia A.A. Diagnostika i lechenie kognitivnykh narushenii posle insul'ta. Med. sovet. 2015; 10: 14–21. [in Russian]
25. Preobrazhenskaia I.S., Naumenko A.A. Patogenez, diagnostika i terapiia bolezni Al'tsgeimera. Med. sovet. 2015; 5: 46–54. [in Russian]
26. Kotov A.S., Eliseev Iu.V., Semenova E.I. Bolezn' Al'tsgeimera: ot teorii k praktike. Med. sovet. 2015; 18: 41–4. [in Russian]
27. Rekomendatsii Evropeiskogo Obshchestva po AG. 2013 god. URL: http://gipertonik.ru/recommendation-european-society. [in Russian]
28. Poole-Wilson PA, Lubsen J, Kirwan BA et al. On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.
29. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64.
30. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046–52.
31. Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
32. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
33. PATS Collaborating Group. Post-stroke antihypertensive treatment study: preliminary results. Clin Med J 1995; 108: 710–7.
34. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
35. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
36. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
37. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20.
38. Bufalino VJ, Masoudi FA, Stranne SK et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167–79.
39. Trukhan D.I., Mazurov A.L. Mild to moderate cognitive impairment: current issues of diagnosis and treatment in primary health care. Consilium Medicum. 2016; 18 (2): 74–80. [in Russian]
40. Zakharov V.V., Vakhnina N.V. Diagnosis and treatment of cognitive impairments. Neurology and Rheumatology. Consilium Medicum (Suppl.). 2014; 1: 21–7. [in Russian]
41. Dlugaj M, Winkler A, Weimar C et al. Anemia and Mild Cognitive Impairment in the German General Population. J Alzheimers Dis 2015; 49 (4): 1031–42.
42. Papachristou E, Ramsay SE, Papacosta O et al. The Test Your Memory cognitive screening tool: sociodemographic and cardiometabolic risk correlates in a population-based study of older British men. Int J Geriatr Psychiatry 2015 Oct 21.
43. Knopman DS, Beiser A, Machulda MM et al. Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology. 2015; 85 (19): 1712–21.
44. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. Climacteric 2015; 18 (5): 678–89.
45. Booker A, Jacob LE, Rapp M et al. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 2016 Jan 8; 1–7.
46. van Rooij FG, Kessels RP, Richard E et al. Cognitive Impairment in Transient Ischemic Attack Patients: A Systematic Review. Cerebrovasc Dis 2016; 42 (1–2): 1–9.
47. Tzivian L, Dlugaj M, Winkler A et al. Long-Term Air Pollution and Traffic Noise Exposures and Mild Cognitive Impairment in Older Adults: A Cross-Sectional Analysis of the Heinz Nixdorf Recall Study. Environ Health Perspect 2016 Feb 5.
48. Zakharov V.V., Drozdova E.A. Kognitivnye narusheniia u bol'nykh s cherepno-mozgovoi travmoi. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2013; 4: 88–93. [in Russian]
49. Zakharov V.V., Vakhnina N.V. Kognitivnye narusheniia pri depressii. Effektivnaia farmakoterapiia. 2015; 1: 18–26. [in Russian]
50. Strokov I.A., Zakharov V.V., Strokov K.I. Diabeticheskaia entsefalopatiia. Sovremennoe sostoianie problemy. Doktor.Ru. 2013; 7–2: 29–35. [in Russian]
51. Kuimov A.D., Golubkova M.E. Korrektsiia kognitivnykh narushenii u bol'nykh s serdechno-sosudistymi zabolevaniiami. Neurology and Rheumatology (Suppl. to the Consilium Medicum). 2012; 2: 49–51. [in Russian]
52. Chukhlovina M.L. Nevrologicheskie oslozhneniia serdechno-sosudistykh zabolevanii. Handbook for Practitioners Doctors. 2012; 8: 51–3. [in Russian]
53. Zakharov V.V., Vakhnina N.V., Ostroumova O.D. Korrektsiia kognitivnykh narushenii u patsienta s arterial'noi gipertenziei i serdechnoi nedostatochnost'iu: kak sdelat' pravil'nyi vybor. Effektivnaia farmakoterapiia. 2014; 12: 12–8. [in Russian]
54. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347–51.
55. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752–68.
56. Mason RP, Leeds PR, Jacob PF et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448–56.
57. Thibault O, Porter NM, Chen KC. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417–33.
58. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543–4.
59. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81–8.
60. Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease. Mt Sinai J Med 2010; 77: 43–9.
61. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589–97.
62. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631–6.
63. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103–13.
64. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8: 16–30.
65. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217–33.
66. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Ab accumulation by targeting both the production and the clearance of Ab across the blood-brain barrier. Mol Med 2011; 17 (3–4): 149–62.
67. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71–4.
68. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26: 157–63.
69. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20: 903–14.
70. Spinar J, Vitovec J. AII antagonists in the treatment of hypertension and prevention of CVA. Vnitr Lek 2013; 59 (1): 71–8.
71. Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents. Curr Med Res Opin 2013; 29 (9): 1045–54.
72. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014; 19 (6): 501–15.
73. Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160–9.
74. Ostroumova O.D. Prevention of stroke and dementia in high-risk patients. Consilium Medicum. 2015;17 (10): 73–6. [in Russian]
75. Chursina T.Ia., Mikhalev K.A. «Farmakologicheskii labirint», ili Poiski optimal'noi kombinatsii. Arterial'naia gipertenziia. 2012; 5: 32–8. [in Russian]
76. Korzh A.N., Govbakh I.A. Ratsional'naia kombinirovannaia terapiia arterial'noi gipertenzii: optimizatsiia profilaktiki tserebrovaskuliarnykh narushenii. Arterial'naia gipertenziia. 2013; 5: 9–15. [in Russian]
77. Kriuchkova O.N., Itskova E.A., Lutai Iu.A., Turna E.Iu. Novye gorizonty fiksirovannoi antigipertenzivnoi terapii. Krymskii terapevticheskii zhurn. 2015; 17 (2): 41–8. [in Russian]
78. Enanorm (Enanorm). Instruktsiia po primeneniiu, protivopokazaniia, sostav i tsena. URL: http://www.rlsnet.ru/tn_index_id_49497.htm [in Russian]
79. Trukhan D.I., Pozdnyakov Yu.M. Actual aspects of rational pharmacotherapy in cardiology. Pros and cons fixed and arbitrary combinations of antihypertensive drugs. Consilium Medicum. 2016; 18 (1): 25–31. [in Russian]
80. Trukhan D.I., Pozdniakov Iu.M. Lechenie arterial'noi gipertenzii problemy real'noi klinicheskoi praktiki. Spravochnik poliklinicheskogo vracha. 2016; 3: 4–8. [in Russian]

Д.И.Трухан*1, Е.Л.Давыдов2

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12;
2 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого» Минздрава России. 660022, Россия, Красноярск, ул. Партизана Железняка, д. 1
*dmitry_trukhan@mail.ru

________________________________________________